Table A6.
Number of ER+ve patients prescribed tamoxifen and aromatase inhibitors by age during April–July 2015 among women recorded with ER+ve breast cancer in England during 1995–2015.
| Age as of April 2015 | ER+ve patients with a tamoxifen prescription | ER+ve patients with an aromatase inhibitor prescription | ER+ve patients |
|---|---|---|---|
| 16-39 | 1,622 | 169 | 2,881 |
| 40-44 | 2,836 | 370 | 4,734 |
| 45-49 | 6,113 | 1,133 | 10,107 |
| 50-54 | 8,139 | 3,944 | 16,290 |
| 55-59 | 3,495 | 6,392 | 14,467 |
| 60-64 | 2,381 | 8,197 | 15,403 |
| 65-69 | 3,152 | 10,233 | 19,648 |
| 70-74 | 2,381 | 7,346 | 14,623 |
| 75-79 | 1,466 | 5,340 | 10,242 |
| 80-84 | 1,157 | 4,533 | 7,857 |
| 85-89 | 713 | 3,055 | 4,989 |
| 90+ | 465 | 1,942 | 2,999 |